Cargando…

Initial vancomycin versus metronidazole for the treatment of first-episode non-severe Clostridioides difficile infection

OBJECTIVE: Clostridioides difficile infection (CDI) is the leading cause of infectious nosocomial diarrhea. Although initial fidaxomicin or vancomycin treatment is recommended by most major guidelines to treat severe CDI, there exists varied recommendations for first-episode non-severe CDI. Given th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Kevin, Beckett, Patricia, Abouanaser, Salaheddin, Smieja, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495603/ https://www.ncbi.nlm.nih.gov/pubmed/36168487 http://dx.doi.org/10.1017/ash.2021.194

Ejemplares similares

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. difficile Infection
por: Goldeh, Peyman, et al.
Publicado: (2017)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

Plasmid-mediated metronidazole resistance in Clostridioides difficile
por: Boekhoud, Ilse M., et al.
Publicado: (2020)

Vancomycin vs metronidazole use for the treatment of Clostridioides difficile infection in a tertiary care hospital in Saudi Arabia
por: Alhameed, Abrar F., et al.
Publicado: (2023)

Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
por: Yin, Jianyi, et al.
Publicado: (2019)

Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates
por: Smits, Wiep Klaas, et al.
Publicado: (2022)

Effective Dosage of Oral Vancomycin in Treatment for Initial Episode of Clostridioides difficile Infection: A Systematic Review and Meta-Analysis
por: Chiu, Chia-Yu, et al.
Publicado: (2019)

Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin
por: Merchante, Nicolás, et al.
Publicado: (2023)

Corrigendum to: Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridioides difficile Infections
por: Yin, Jianyi, et al.
Publicado: (2020)

Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model
por: Yang, Jingpeng, et al.
Publicado: (2022)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Correction to: Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin
Publicado: (2023)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Efficacy of Oral Vancomycin, Oral Metronidazole, or IV Metronidazole Prophylaxis at Reducing the Risk of Clostridium difficile Recurrence
por: O’Connell, Matthew, et al.
Publicado: (2017)

840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in Clostridioides difficile
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Recurrence and mortality following treatment for Clostridum difficile infection with metronidazole or vancomycin
por: Stevens, V, et al.
Publicado: (2015)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity
por: Di, Xiuzhen, et al.
Publicado: (2015)

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile
por: Boekhoud, Ilse M, et al.
Publicado: (2021)

Detection of Plasmid-Mediated Resistance to Metronidazole in Clostridioides difficile from River Water
por: Cizek, Alois, et al.
Publicado: (2022)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

488. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients
por: Vega, Ana, et al.
Publicado: (2018)

Impact of subinhibitory concentrations of metronidazole on proteome of Clostridioides difficile strains with different levels of susceptibility
por: Doan, Tri-Hanh-Dung, et al.
Publicado: (2020)

Impact of Subinhibitory Concentrations of Metronidazole on Morphology, Motility, Biofilm Formation and Colonization of Clostridioides difficile
por: Doan, Tri-Hanh-Dung, et al.
Publicado: (2022)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

500. Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection With History of Multiple Recurrences
por: Lee, Christine, et al.
Publicado: (2018)

Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile
por: Olaitan, Abiola O., et al.
Publicado: (2023)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Effect of sub-MIC values of metronidazole, ciprofloxacin, and imipenem on the growth and toxin production in Clostridioides difficile
por: Shayegan Mehr, Farahnaz Sadat, et al.
Publicado: (2019)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4vdqf4271poam1v9o88kt7b3m5